首页> 外文期刊>Diabetes care >Utility of Plasma Concentration of Trimethylamine N-Oxide in Predicting Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes
【24h】

Utility of Plasma Concentration of Trimethylamine N-Oxide in Predicting Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes

机译:三甲胺N-氧化物的血浆浓度预测1型糖尿病患者心血管和肾并发症的纯化性

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE Trimethylamine N-oxide (TMAO) is suggested as an independent gut microbiota-derived risk factor for cardiovascular and renal disease. We investigated associations between plasma TMAO concentrations and cardio-renal outcomes in a prospective study of individuals with type 1 diabetes. RESEARCH DESIGN AND METHODS Plasma TMAO was measured at baseline in 1,159 individuals with type 1 diabetes (58% male, mean +/- SD age 46 +/- 13 years). End points were all-cause and cardiovascular mortality, cardiovascular disease (CVD), and renal events tracked from national registries. Associations between TMAO and end points were tested using Cox regression models. RESULTS After 15.0 (6.7-19.3) (median [interquartile range]) years of follow-up, we recorded all-cause and cardiovascular mortality (n = 363 and 120, respectively), combined CVD (n = 406), coronary outcome (myocardial infarction and coronary intervention) (n = 163), stroke (n = 115), hospitalization for heart failure (n = 81), and end-stage renal disease (n = 144). In univariate analyses, higher TMAO concentrations were associated with all end points (P <= 0.005). Except for stroke and heart failure, all end points remained significantly associated with higher TMAO concentrations after adjustment for conventional cardiovascular risk factors (P <= 0.003). After further adjustment for baseline estimated glomerular filtration rate (eGFR), results became insignificant for all end points. TMAO was inversely associated with baseline eGFR (R-2 = 0.29; P < 0.001). CONCLUSIONS In individuals with type 1 diabetes, higher concentrations of plasma TMAO were associated with mortality, CVD events, and poor renal outcome, independent of conventional risk factors. However, the association became insignificant after further adjustment for baseline eGFR. This could reflect TMAO as a renal function marker or a risk factor for micro- and macrovascular complications mediated through impaired renal function.
机译:目的三甲胺N-氧化物(TMAO)被建议作为心血管和肾脏疾病的独立肠道微生物衍生的危险因素。我们研究1型糖尿病患者的前瞻性研究血浆TMAO浓度和心肾结果之间的关联。研究设计和方法血浆TMAO在基线测量在1159个个人与1型糖尿病患者(58%为男性,平均+/- SD年龄46 +/- 13岁)。终点是全因死亡率和心血管死亡率,心血管疾病(CVD),并从国家登记追踪肾脏事件。 TMAO和终点之间的关系应用Cox回归模型进行测试。结果后15.0(6.7-19.3)(中位数[四分位数间距])年的随访的,我们记录了全因死亡率和心血管死亡率(分别为N = 363和120),合并的CVD(N = 406),冠状动脉结果(心肌梗塞和冠状动脉介入)(N = 163),中风(N = 115),住院心脏衰竭(N = 81),和终末期肾脏疾病(N = 144)。在单变量分析中,较高的TMAO浓度与所有端点(P <= 0.005)相关联。除了中风和心脏衰竭,所有端点仍然显著具有较高浓度的TMAO调整为常规的心血管危险因素(P <= 0.003)后相关联。后基线进一步调整估计的肾小球滤过率(eGFR),结果成为微不足道的所有端点。 (P <0.001 R-2 = 0.29)TMAO呈负基线的eGFR相关联。结论1型糖尿病患者,血浆TMAO的较高浓度与死亡率,心血管事件和肾脏预后差,传统的独立危险因素有关。然而,该协会成为后基线eGFR的进一步调整微不足道。这可能反映了TMAO作为肾功能标记或通过肾功能受损介导的微血管和大血管并发症的危险因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号